Kidney injury molecule-1 (KIM-1) is a receptor for the "eat me" signal, phosphatidylserine, on apoptotic cells. The specific upregulation of KIM-1 by injured tubular epithelial cells (TECs) enables them to clear apoptotic cells (also known as efferocytosis), thereby protecting from acute kidney injury. Recently, we uncovered that KIM-1 binds directly to the ␣-subunit of heterotrimeric G12 protein (G␣12) and inhibits its activation by reactive oxygen species during renal ischemia-reperfusion injury (Ismail OZ, Zhang X, Wei J, Haig A, Denker BM, Suri RS, Sener A, Gunaratnam L. Am J Pathol 185: [1207][1208][1209][1210][1211][1212][1213][1214][1215] 2015). Here, we investigated the role that G␣12 plays in KIM-1-mediated efferocytosis by TECs. We showed that KIM-1 remains bound to G␣12 and suppresses its activity during phagocytosis. When we silenced G␣12 expression using small interefering RNA, KIM-1-mediated engulfment of apoptotic cells was increased significantly; in contrast overexpression of constitutively active G␣12 (QLG␣12) resulted in inhibition of efferocytosis. Inhibition of RhoA, a key effector of G␣12, using a chemical inhibitor or expression of dominant-negative RhoA, had the same effect as inhibition of G␣12 on efferocytosis. Consistent with this, silencing G␣12 suppressed active RhoA in KIM-1-expressing cells. Finally, using primary TECs from Kim-1 ϩ/ϩ and Kim-1 Ϫ/Ϫ mice, we confirmed that engulfment of apoptotic cells requires KIM-1 expression and that silencing G␣12 enhanced efferocytosis by primary TECs. Our data reveal a previously unknown role for G␣12 in regulating efferocytosis and that renal TECs require KIM-1 to mediate this process. These results may have therapeutic implications given the known harmful role of G␣12 in acute kidney injury.
G protein; phagocytosis; G␣ 12; kidney injury molecule-1 (KIM-1); kidney ACUTE KIDNEY INJURY (AKI) is a serious medical condition that affects up to one in five hospitalized patients globally, and for which there is no effective treatment (12, 13, 97) . The most common pathoetiological mechanism causing AKI is ischemiareperfusion injury (IRI) (7) . Renal proximal tubular epithelial cells (TECs) are particularly susceptible to ischemic injury (40, 92) . Injury or death of TECs is widely recognized as a major pathogenic step in AKI (7, 63) . Recent work suggests that both apoptosis (15, 94) and different forms of necrosis (e.g., necroptosis) coexist in AKI (63) . While apoptotic cells (or bodies) are rapidly cleared by efferocytosis without triggering in-flammation (66) , necrotic cells and uncleared apoptotic cells undergoing secondary necrosis (that lack an intact plasma membrane) (93, 101) passively release immunogenic damage-associated molecular pattern proteins (DAMPs), contributing to inflammation and secondary tissue damage in AKI (64, 105) .
During AKI, TECs take on attributes of professional phagocytes and rapidly clear apoptotic and necrotic cells through a process known as efferocytosis (42, 62, 106, 110) . Phagocytes recognize apoptotic cells via cell-surface receptors that directly or indirectly bind to "eat me" signals displayed on the surface of dying cells (25, 60) . We (42) and others (56, 91) identified kidney injury molecule-1 (KIM-1), a novel phagocytic receptor for phosphatidylserine that is specifically upregulated on apical surface of TECs following injury (37, 43) . Recently, we reported that Kim-1-deficient mice succumb to worse tissue injury and mortality after ischemic AKI (48) . In addition, Yang et al. (110) have highlighted the importance of phagocytic clearance of apoptotic cells in AKI by showing that mice expressing a mucin-domain deletion mutant of Kim-1 with impaired phagocytic function are more prone to AKI as a result of exaggerated inflammation (110) . Thus the upregulation of KIM-1 on TECs seems to play a protective role in AKI via efferocytosis.
KIM-1 is also known as T cell immunoglobulin and mucin domain-containing protein 1 (TIM-1) (68) or hepatitis A virus cellular receptor-1 (HAVCR1) (51) , and is encoded by the HAVCR1 gene. Both mouse (termed Kim-1) and human proteins (KIM-1) are small type I transmembrane glycoproteins that belongs to the TIM family of proteins (29) . The human TIM family consists of TIM-1 (28, 43, 68, 91) , TIM-3 (20, 77) , and TIM-4 (56, 91) , which are conserved between mice and humans and bind directly to phosphatidylserine (29, 42, 43, 56, 91) . KIM-1 is expressed by mast cells, B cells, activated CD4 T cells, and injured TECs (29, 37) . The structure of KIM-1 consists of an IgVϪlike domain, a mucin domain, a transmembrane domain, and an intracellular (C-terminal) tail that has been implicated in cell signaling in differentiated T cells (16, 18, 43, 91) and B cells (112) . The crystal structure of the IgV-like domain of KIM-1 has been solved and reveals that it contains a conserved binding pocket termed the metal iondependent ligand-binding site (MILIBS) (9, 20, 91) that allows for highly specific recognition of phosphatidylserine (29, 91) .
The process of apoptotic cell recognition and engulfment is a highly complex and regulated process (2) . Clustering of cell-surface KIM-1 by phosphatidylserine on apoptotic cell leads to formation of phagocytic cups on TECs (29) . Ligand recognition triggers cell signaling that ultimately results in reorganization of the cell cytoskeleton to enable the phagocyte to engulf, internalize, and degrade the cell corpses (10, 39) . Efferocytosis requires dynamic cytoskeletal remodeling that is mediated by Rho family of small GTPases such as RhoA and Rac1 (60, 65, 76, 84) . Like all G proteins, RhoA and Rac1 cycle between GDP-bound inactive and GTP-bound active conformations regulated by GTP exchange factors (GEFs) or GTPase-activating proteins (GAPs), respectively (34, 85, 86) . Although both RhoA and Rac1 belong to same family, they differ in their action: Rac1 induces polymerization of actin, leading to membrane ruffles and filopodia formation, while RhoA induces actin assembly into bundles and stress fibers (36) . While the activation of Rac1 seems to be an evolutionarily conserved event in efferocytosis (53, 54, 83) , some have proposed an inhibitory role for RhoA (27, 79, 83, 114) .
Recently, we uncovered that KIM-1 interacts with the ␣-subunit of heterotrimeric G 12 proteins (G␣ 12 ) and this interaction suppresses downstream injury pathways triggered by G␣ 12 activation by reactive oxygen species (ROS) in TECs during renal IRI (48) . G␣ 12 belongs to the G 12 class of G proteins (23, 102) . It is ubiquitously expressed and has pleiotropic effects on cells, including inducing proliferation, focal adhesion assembly/disassembly, and cytoskeletal reorganization (25, 59, 78) . Many of these effects, including actin stress fiber formation, are mediated downstream by G␣ 12 -dependent activation of RhoA via Rho GEFs (98), including LARG (31), PDZ-RhoGEF (58) , and p115 RhoGEF (45) .
Herein, we investigated the role of G␣ 12 in KIM-1-mediated efferocytosis using cell culture models and primary TECs isolated from the kidneys of mice. We revealed that KIM-1 expression serves to suppress G␣ 12 activation to permit phagocytosis of apoptotic cells. In addition, we show that the inhibitory effect of G␣ 12 on efferocytosis is mediated by downstream activation of RhoA. Finally, we showed that primary TECs rely entirely on KIM-1 for efferocytosis and confirm the inhibitory role of G␣ 12 in this process.
EXPERIMENTAL PROCEDURES
Cell culture and materials. Human embryonic kidney 293 (HEK-293) cells and porcine proximal tubule epithelial cells (LLC-PK 1) were cultured at 37°C in 5% (vol/vol) CO 2 incubator and maintained in DMEM (Invitrogen, Carlsbad, CA) containing 10% FBS (Invitrogen). HEK-293 cells stably expressing KIM-1-green fluorescent protein (GFP; herein referred to as HEK-293-KIM-1-GFP), KIM-1 with no tag (HEK-293-KIM-1), pcDNA-GFP (HEK-293-pcDNA), as well as LLC-PK 1 stably expressing KIM-1 (LLC-PK1-KIM-1) and pcDNA (LLC-PK1-pcDNA) were generated by transfecting with plasmid constructs encoding either KIM-1 or a control vector using Lipofectamine 2000 (Life Technologies, Thermo Fisher Scientific, Rockford, IL). Several single-cell clones were selected using 800 g/ml geneticin (G418) sulfate (Santa Cruz Biotechnology, Santa Cruz, CA). Cells expressing high levels of KIM-1 were used for further experiments and maintained in DMEM containing 10% FBS and 800 g/ml G418. Primary TECs isolated from 2-to 4-wk-old C57BL/6 mice were cultured for the first 6 days in serum-free DMEM:F-12 mixed media (1:1) supplemented with 5% ITS (Invitrogen), 5% penicillin-streptomycin solution (Invitrogen), 0.5 g/ml of mouse EGF (Peprotech, Rocky Hill, NJ), and 50 ng/ml hydrocortisone (Thermo Fisher Scientific). Thereafter, TECs were cultured with the same media after further supplementation with 5% FBS as described earlier (95) . All chemicals were purchased from Sigma (Sigma-Aldrich, St. Louis, MO) unless stated otherwise. The pH-sensitive dye pHrodo Red succinimidyl ester (pHrodo Red SE), Alexa Fluor 555 goat anti-mouse, and 4,6-diamidino-2-phenylindole (DAPI) were purchased from Life Technologies, and rhodamine phalloidin from Cytoskeleton (Denver, CO). G␣ 12 (1:500) and actin (1:1,000) antibodies were purchased from Santa Cruz Biotechnology. PE-conjugated antihuman KIM-1 (1:100, clone 1D12) and PE-conjugated mouse IgG1 isotype control (1:100, MOPC-21) were purchased from Biolegend (San Diego, CA). Allophycocyanine (APC)-conjugated anti-mouse Tim-1 rat IgG2B (1:100, clone AF1817A) and APC-conjugated rat IgG2B isotype control (1:100) were obtained from R&D Systems (Minneapolis, MN). RhoA-specific monoclonal antibodies and nonhydrolyzable GTP analog were purchased from Cytoskeleton. Anti-KIM-1 (human) antibody (PA4145) was generated by immunizing rabbits against the cytosolic domain of KIM-1 (Life Technologies) as previously described (3). A KIM-1 antibody binding to the mucin domain of KIM-1 (AKG7) was kindly provided by Dr. J. V. Bonventre (Harvard Medical School, Boston, MA). Complete Mini EDTAfree protease inhibitor cocktail tablets were purchased from Roche (Roche Diagnostics, Basel, Switzerland). A Rho inhibitor (cell-permeable C3 transferase) was purchased from Cytoskeleton, and a Rho kinase (ROCK) inhibitor (Y27632) and Rac1 inhibitor (NSC23766) were purchased from EMD Millipore (Billerica, MA). Plasmid constructs for G␣ 12, RhoA, and Rac1 were kindly provided by Dr. Bradley Denker (Harvard Medical School, Boston, MA), and plasmid constructs for KIM-1 were from Dr. Bonventre. Either Lipofectamine 2000 and Dharmafect 1 (Thermo Fisher Scientific) were used for transfecting plasmid and small interfering (si) RNA, respectively.
Mice. Wild-type C57BL/6 (Kim-1 ϩ/ϩ ) mice were obtained from the Jackson Laboratory. C57BL/6 Kim-1-deficient mice (Kim-1 Ϫ/Ϫ ) were obtained from Dr. Andrew N. J. McKenzie (MRC Laboratory of Molecular Biology, Cambridge, UK), and these were generated by targeted disruption of mouse havcr1 Ϫ/Ϫ in mouse embryonic stem cells as described previously (104) . All animal procedures were performed in accordance with the Western University Animal Use Subcommittee (protocol 210 -230).
Phagocytosis assay and FACS analysis. To prepare apoptotic cells for phagocytosis assay, thymocytes were harvested from 3-to 6-wkold C57BL/6 mice, and apoptosis was induced by UV exposure for 5 min followed by incubation overnight at 37°C in a 5% CO2 incubator in DMEM media supplemented by 10% FBS and 1% penicillinstreptomycin solution. Apoptotic and necrotic primary TECs were generated by exposing the cells to UV for 5 min or heat-shocking at 65°C for 15 min, respectively. Apoptotic and necrotic cells were stained with pH-sensitive dye pHrodo Red SE at a final concentration of 150 nM for 30 min at room temperature. Labeled apoptotic and necrotic cells were washed twice with 1ϫ PBS to remove excess dye. The cells were counted, and 3 ϫ 10 6 were added to each well of six-well plates (15 ϫ 10 6 for 10-cm plates) and incubated for various time points at 37°C in a 5% CO2 incubator. Cells were then placed on ice for 30 min to reduce nonspecific binding of apoptotic cells. The plates were then washed three times with ice-cold PBS, and adherent cells were collected with 5 mM EDTA-PBS and resuspended with FACS buffer (PBS, 2% calf serum, and 0.1% sodium azide) for flow cytometric analysis. For KIM-1-surface staining, TECs were exposed to blocking solution containing PBS and 10% goat serum for 15 min, followed by incubation for 30 min at room temperature with either PE-conjugated anti-KIM-1 (human) or APC-conjugated anti-Tim-1 (mouse), and their respective isotype control antibodies at a concentration of 1:100. All samples were analyzed using a BD LSR II flow cytometer (BD Biosciences, San Jose, CA). The percentage of phagocytic cells that had internalized the apoptotic cell(s) was calculated and graphed as %phagocytosis. Engulfed cells with low fluorescence representing cells that were adherent, but not internalized, were excluded from the analysis (80) .
Immunoprecipitation and Western blotting. HEK-293 cells were lysed with ice-cold lysis buffer [25 mM HEPES, 150 mM NaCl, 15 mM MgCl2, 1% Triton X-100, and Complete Mini EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics)]. For immunoprecipitation experiments, cell extracts containing 1.0 -1.5 mg protein/ml were incubated with 10 g of G␣12, KIM-1 (PA4145), or rabbit IgG (control) antibody and 20 l of protein-A/G-Sepharose beads (Santa Cruz Biotechnology) at 4°C overnight. The recovered beads were then centrifuged, washed three times with lysis buffer, and suspended in 20 l of SDS sample buffer and heated at 100°C for 5 min. Lysates (representing 5% of total lysate) and immunoprecipitates were separated under reducing conditions and transferred to polyvinylidene difluoride (PDVF) membranes (EMD Millipore). PDVF membranes were subsequently probed with antibodies specific to surface KIM-1 (AKG7, 1:3 dilution), the cytosolic domain of KIM-1 (PA 4145, 1:1,500 dilution), G␣12 (1:500 dilution), actin (1:1,000 dilution), or RhoA (1:500 dilution). The signal was visualized using the appropriate horseradish peroxidase-conjugated secondary antibodies, Luminata Forte ECL Western blot detection reagent (EMD Millipore), and chemiluminescence using film (Biomax Denville Scientific, South Plainfield, NJ) or the ChemiDoc MP System (Bio-Rad Laboratories, Hercules, CA).
GST-tetratricopeptide repeat pull down. A construct of GST-fused tetratricopeptide repeat (TPR) domain was kindly provided by Dr. N. Dhanasekaran (Temple University, Philadelphia, PA). GST-TPR protein was purified from Escherichia coli, as described earlier (107) . Cells were lysed with ice-cold lysis buffer (20 mM HEPES, pH 8.0), 2 mM MgCl2, 1 mM EDTA, 1 mM DTT, 0.5% Triton X-100, and Complete Mini EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics). One milligram of protein lysate and Ӎ1 g of GST-TPR-coupled glutathione-agarose beads were incubated together at 4°C for 5 h (48, 107) . Both lysate and pull-down samples were analyzed by SDS-PAGE and Western blotting to represent total and active G␣12 in these samples, respectively. Lysates loaded with the nonhydrolyzable GTP analog (GTP␥S) or GDP (Cytoskeleton) were used as a positive or negative control, respectively.
Cell viability and death assays. TECs were grown to a confluent monolayer and subjected to different treatments before testing for viability using propidium iodide (PI; Biolegend) or annexin V labeling (Biolegend). The samples were then analyzed using a BD LSR II flow cytometer.
Immunofluorescence and confocal microscopy. HEK-293 cells were cultured at subconfluent density on poly-D-lysine hydrobromide (Sigma-Aldrich)-coated glass coverslips and transfected with various GFP-tagged G␣12 as indicated or small interfering (si) RNA against G␣ 12. Cells were then fixed with 4% paraformaldehyde followed by counterstaining of the nucleus with DAPI (0.5 g/ml). For surface staining of KIM-1 using the AKG antibody, the cells were blocked with 1% BSA in 1ϫ PBS for 1 h at room temperature, followed by incubation of the anti-KIM-1 antibody overnight. Cells were then washed and labeled with Alexa 555-conjugated anti-mouse at a concentration of 1:1,000. To stain the actin cytoskeleton, cells were permeabilized with 0.25% Triton X-100 in 1ϫ PBS for 5 min and then stained with rhodamine phalloidin for 30 min according to the manufacturer's recommendation (Cytoskeleton). Coverslips were mounted using Shandon-Mount permanent mounting (Thermo Fisher Scientific) and viewed using a FLUOVIEW X83I confocal microscope (Olympus, Tokyo, Japan). Data were acquired and analyzed using a FLUOVIEW FV10 ASW 4.0 viewer and ImageJ 1.49 software (National Institutes of Health, Bethesda, MD) to determine the Van Steensel score for colocalization of KIM-1 and G␣12. The colocalization score was calculated using five random fields/sample and from three independent experiments. Quantification of the number of bound apoptotic cells was assessed in eight random fields/sample and four independent experiments.
Silencing G␣12 in HEK-293 and TECs using siRNA. ON Target plus Smart pool siRNA against G␣12-specific and a nontargeting pool (Control siRNA) were purchased from Dharmacon (Thermo Fisher Scientific). Cells were transfected with 50 nM of siRNA using Dharmafect1 for 24 h before further analysis of the knockdown.
RhoA activation. Rho activation was determined using Rhotekin-RBD (Rho-binding domain) beads according to the manufacturer's instructions (Cytoskeleton) and as described elsewhere (113) . Lysate and pull-down samples were analyzed by SDS-PAGE and Western blotting to detect total and active RhoA respectively. Control lysates were incubated with GDP (1 mM, negative control) or GTP␥S (200 M, positive control) for 15 min before addition of Rhotekin-RBD beads. The ratio of active to total RhoA was determined from densitometric values determined by Western blotting. For siRNA experiments where RhoA activation was measured, we used the G-LISA RhoA Activation Assay from Cytoskeleton due to the small amount of the protein available and its higher sensitivity compared with the pull-down assay.
Quantification and statistics. Western blots were scanned, and the band intensity was quantified using ImageJ 1.49 software after subtraction of the background and determination of the linear range. The relative change in expression of the band intensity was obtained as follows. First, we calculated the ratio of the densitometric reading for the relevant band (e.g., active G␣ 12) to that of its loading control (e.g., total G␣12). Then, we divided each of the ratios by the ratio obtained for the control treatment to obtain a treatment value relative to the control value (i.e., relative to a control of 1). Statistical analysis was done using GraphPad Prism (Graph Pad Software, La Jolla, CA) or IBM SPSS statistic 22 (IBM, Armonk, NY). Significance was determined by using one-way ANOVA with Tukey's post hoc test (for GST-TPR data) or an unpaired t-test. 12 during efferocytosis. KIM-1 is not expressed by healthy TECs but is upregulated more than any other protein in TECs after AKI (1, 55) . Exogenous overexpression of KIM-1 in cultured cell lines is often used as a model for KIM-1 upregulation in TECs during AKI and for studying its phagocytic function (32, 42) . In choosing an appropriate cell line to study KIM-1-G␣ 12 interactions in vitro, we first determined the level of endogenous G␣ 12 expression in a variety of routinely used cell lines for studying phagocytosis (103) . We found that HEK-293 cells expressed sufficient G␣ 12 to enable its detection by Western blotting (Fig. 1A ). We failed to detect endogenous G␣ 12 protein expression in cells that spontaneously express KIM-1, such as the human renal adenocarcinoma cell line, 769-P, which are also routinely used to study KIM-1-mediated efferocytosis (32, 42, 56) . To study the interaction of KIM-1 and G␣ 12 during KIM-1-mediated efferocytosis, we generated HEK-293 cells that stably expressed human KIM-1 bearing a C-terminal GFP-tag (HEK-293-KIM-1-GFP) and determined the efficiency and kinetics of apoptotic engulfment of these cells (43, 48) . To distinguish between bound and internalized apoptotic cells by flow cytometry, apoptotic targets were labeled with a pH-dependent fluorescent dye (pHrodo) that exhibits higher fluorescence upon entry of apoptotic cells into acidic compartments such as phagolysosomes (32, 72, 81) . HEK-293-KIM-1-GFP cells were significantly more efficient at engulfing apoptotic cells (40 vs. 8%, P Ͻ 0.05) relative to cells stably transfected with control vector (pcDNA-GFP) ( Fig. 1B) . We also visualized the HEK-293-KIM-1-GFP cells during efferocytosis using confocal microscopy (Fig. 1C ). Phagocytic cups formed at the cell surface within 15 min of adding labeled apoptotic cells. The inhibition of apoptotic cell engulfment by KIM-1-expressing HEK-293 with cytochalasin D further confirmed that the uptake of Translational Physiology F609 G␣12 INHIBITS KIM-1-MEDIATED EFFEROCYTOSIS apoptotic cells required actin polymerization that is typical of efferocytosis ( Fig. 1D) (50) .
RESULTS

KIM-1 interacts with G␣
We previously demonstrated that the cytosolic domain of KIM-1 interacts with G␣ 12 and inhibits its activation by various G␣ 12 agonists (48). To investigate whether KIM-1 interacts with G␣ 12 during efferocytosis, we performed co-immunoprecipitation of G␣ 12 with KIM-1 in HEK-293-KIM-1-GFP cells before and after exposure to apoptotic cells. We found that the interaction between G␣ 12 with KIM-1 in cells did not depend on apoptotic cell stimulation of HEK-293-KIM-1-GFP cells ( Fig. 2A ). Using densitometric analysis, we found that the interaction of G␣ 12 with KIM-1 after stimulation with apoptotic cells was strongest at 30 min, which correlated with formation of phagocytic cups (Fig. 1C) . These data were further confirmed using GST-G␣ 12 pull down of KIM-1 in lysates prepared from HEK-293 cell stably expressing KIM-1 before and after exposure to apoptotic cells (Fig. 2B) .
To visualize the interaction of G␣ 12 with KIM-1 in cells, we cotransfected HEK-293 cells with KIM-1 and GFP-tagged G␣ 12 , and examined the kinetics of G␣ 12 -KIM-1 colocalization before and after addition of apoptotic cells (Fig. 2C ). In keeping with our previous work (48), we observed that the colocalization of KIM-1 with G␣ 12 in these cells neither required nor was it perturbed by exposure to apoptotic cells. Moreover, we calculated the quantification of the change in colocalization at the vicinity of apoptotic cells using the Van Steensel approach (6) . We failed to reveal any significant difference in colocalization between apoptotic cell-unstimulated and apoptotic cell-stimulated conditions (Fig. 2D) . Together, the above results suggested that KIM-1 constitutively interacts with G␣ 12 in cells and remains so during efferocytosis.
KIM-1 downregulates G␣ 12 activity during KIM-1-mediated efferocytosis. Efferocytosis involves a series of events that begins with recognition of eat me signals on apoptotic cells by the phagocytic receptor(s) on the phagocyte, which then leads to phagocytic cup formation, which then sets off a cascade of intracellular signaling events including activation of various GTPases that mediate corpse engulfment (24, 54, 83) . Since G␣ 12 is a GTPase, which cycles between active (GTP-bound) and inactive (GDP-bound) status, we sought to investigate whether and how G␣ 12 activity was altered during efferocytosis in our model system. We therefore measured the fraction of active-to-total G␣ 12 cells after feeding them apoptotic cells. We used a wellestablished active-G␣ 12 pull-down assay which utilizes the TPR domain of the downstream effector of G␣ 12 , Ser/Thr phosphatase type 5 (PP5), fused to GST (107) . Western blotting was used to detect both active and total G␣ 12 (107) . In KIM-1-expressing cells, we observed a steady decrease in the level of active G␣ 12 during efferocytosis (Fig. 3A ). This decrease in the level of active G␣ 12 was more pronounced during later stages of efferocytosis (60 -90 min after adding apoptotic cells). On the other hand, we observed no significant change in G␣ 12 activity in control HEK-293 cells exposed to apoptotic cells (Fig. 3B ). Consistent with these results, we observed similar kinetics of G␣ 12 activation when porcine renal proximal TECs (LLC-PK 1 ) stably expressing a C-terminal heme agglutinin (HA)-tagged KIM-1 or control vector (pcDNA) were cotransfected with a G␣ 12 expression construct (data not shown). Together, these data suggested that endogenous G␣ 12 activity may be suppressed by KIM-1 expression in HEK-293 cells during efferocytosis. Since we had already demonstrated in Fig. 1B that KIM-1 expression is required for efferocytosis, these data begged the question of whether G␣ 12 inhibition by KIM-1 was required for efficient efferocytosis. G␣ 12 is a negative regulator of KIM-1-mediated efferocytosis. Although data presented thus far demonstrate that G␣ 12 activity is inhibited during phagocytosis, they did not necessarily imply a functional role for G␣ 12 in KIM-1-mediated efferocytosis. To test this, HEK-293 cells stably expressing KIM-1 (HEK-293-KIM-1) were transfected with a control vector (pcDNA-GFP), vector encoding WT GFP-tagged G␣ 12 (WTG␣ 12 -GFP), or a vector encoding the GFP-tagged constitutively active (GTPase-deficient) mutant of G␣ 12 (QLG␣ 12 -GFP) (70) , and efferocytosis efficiency was studied using flow cytometry. Overexpression of QLG␣ 12 -GFP significantly inhibited engulfment of apoptotic cells by the HEK-293-KIM-1 cells, whereas WTG␣ 12 -GFP expression had little effect on phagocytosis (Fig. 4A ). We obtained similar results when we transfected LLC-PK 1 cells with QLG␣ 12 -GFP (Fig. 4B ). We once again confirmed the effect of QLG␣ 12 -GFP transfection on the phagocytic capacity of HEK-293-KIM-1 cells using confocal imaging by counting the number of apoptotic cells present inside GFP-positive cells (pcDNA-GFP or pcDNA-QLG␣ 12 -GFP) (Fig. 4C) . To test how suppression of G␣ 12 expression would affect efferocytosis, we silenced endogenous G␣ 12 in HEK-293-KIM-1-GFP cells using siRNA ( Fig. 4D ) and performed phagocytosis assays as described above. We found a significant increase in the uptake of apoptotic cells (Fig. 4E ) in conjunction with effective knockdown of G␣ 12 in these cells (Fig. 4D ). Evaluation of phagocytosis by confocal microscopy helped confirm the above results (Fig. 4F) . Together, these data suggested that active G␣ 12 has a negative effect on KIM-1-mediated engulfment of apoptotic cells.
RhoA acts downstream of G␣ 12 to inhibit KIM-1-mediated efferocytosis. G␣ 12 has been shown to transduce signals from GPCR to activate RhoA via Rho guanine nucleotide exchange factors (98) . RhoA belongs to the Rho family of GTPases (11, 35, 100) , which regulate the actin cytoskeleton and efferocy- tosis (74, 76, 83) . To determine the role of RhoA in KIM-1dependent engulfment of apoptotic cells, we inhibited RhoA signaling using a cell-permeable Rho inhibitor (C3 transferase) (30) or its downstream effector ROCK using Y27632 (46, 47) . The inhibition of either RhoA or ROCK activity significantly increased the uptake of apoptotic cells in our system compared with the respective controls (Fig. 5A) . The comparable effects of both inhibitors on apoptotic cell uptake suggested that ROCK might be mediating the inhibitory effect of RhoA on efferocytosis in KIM-1-expressing HEK-293 cells. HEK-293-KIM-1 cells transfected with a vector encoding either WT RhoA or a constitutively activated RhoA mutant (Q62L) significantly inhibited the phagocytic efficiency of these cells compared with the HEK-293-KIM-1 cells transfected with a control vector (Fig. 5B ). Importantly, we were able to reproduce the effects of chemical inhibition of RhoA on efferocytosis when HEK-293-KIM-1 cells were transfected with dominant negative RhoA (T19N), which resulted in a significant increase in phagocytosis (Fig. 5B) . The parallel and negative effects of both activated G␣ 12 and RhoA on KIM-1-mediated efferocytosis suggested that RhoA likely mediated the G␣ 12 -inhibitory effect on phagocytosis. To formally test whether the endogenous RhoA activity was due to G␣ 12 in our cells, we silenced endogenous G␣ 12 expression in HEK-293-KIM-1-GFP cells and measured the RhoA activation using a commercially available pull-down assay that employs the binding domain of Rho effector protein (Rhotekin) fused to GST (46) . Endogenous RhoA activity was significantly inhibited in HEK-293-KIM-1-GFP cells treated with G␣ 12 siRNA but not control siRNA at baseline, at 30 min (early phagocytosis), and at 90 min (late phagocytosis) after of exposure to apoptotic cells (Fig. 5C ). Additionally, HEK-293-KIM-1-GFP cells transfected with a constitutively active mutant of G␣ 12 (QLG␣ 12 ) exhibited significantly increased RhoA activity (Fig. 5D ).
We also examined dynamic RhoA activity during phagocytosis. Following stimulation with apoptotic cells, we observed a gradual increase in the level of active RhoA that peaked at ϳ90 min after the addition of apoptotic cells (Fig. 6A) . On the other hand, there was no discernible pattern of RhoA activation observed in cells not expressing KIM-1 that were also fed apoptotic cells (Fig. 6B ). Taken together, the above results suggested that G␣ 12 -RhoA signaling negatively regulates KIM-1-dependent efferocytosis. Our data are consistent with reports of RhoA and ROCK being negative regulators of efferocytosis mediated by other phagocytic receptors (76, 100) .
Unlike RhoA, Rac1 has been shown to have a conserved and positive role in efferocytosis in both professional and semiprofessional phagocytes that employ a variety of phagocytic receptors to engulf apoptotic cells (82, 83) . Thus we sought to determine the role of Rac1 in KIM-1-mediated efferocytosis. (Fig. 7, A and B) . These data suggested that Rac1 is required for KIM-1-dependent efferocytosis and plays an opposite role to RhoA in corpse engulfment in our cell culture model. KIM-1 is required for efferocytosis by primary proximal TECs and is inhibited by G␣ 12 . Taken together with our previous report (48) showing that KIM-1-expression on TECs suppresses G␣ 12 activation by blocking GTP-loading, our present data suggest that KIM-1-mediated inhibition of endogenous G␣ 12 activation in KIM-1-expressing cells enables efficient efferocytosis. To confirm the inhibitory role of G␣ 12 in a physiologically relevant cell type, we studied primary TECs isolated from mouse kidneys. First, we wished to determine whether KIM-1 is the major efferocytosis receptor in renal TECs, because our findings regarding G␣ 12 would be generalizable to any efferocytosis by TECs. To formally determine whether KIM-1 is absolutely required for efferocytosis by primary TECs or whether there is redundancy (in apoptotic cell receptors) in efferocytosis receptors in TECs, we compared the phagocytic efficiency between primary TECs isolated from WT (Kim-1 ϩ/ϩ ) C57BL/6 and previously generated Kim-1-deficient mice (Kim-1 Ϫ/Ϫ ) mice (104) . As previously reported, ex vivo culturing of TECs from WT mice readily resulted in spontaneous Kim-1 upregulation, presumably because cell culturing is a form cell stress or injury (1, 41, 42) . Compared with Kim-1 ϩ/ϩ TECs, there was an absence of both total Kim-1 protein level and Kim-1 cell-surface expression in TECs isolated from Kim-1 Ϫ/Ϫ , as determined by Western blotting and flow cytometry, respectively (Fig. 8, A and B) . Next, apoptotic cells were fed to the TECs and efferocytosis was measured at different time periods over 24 h. We observed a significant difference in phagocytosis between Kim-1 Ϫ/Ϫ TECs and Kim-1 ϩ/ϩ TECs (Fig. 8C) . Surprisingly, Kim-1-deficient TECs were virtually incapable of uptaking apoptotic cells. To verify these findings using an alternate method, TECs were fed fluorescently labeled apoptotic cells for 3 h and cells were stained for surface Kim-1 and imaged by confocal microscopy (Fig. 8D ). Similar to what was observed using flow cytometry, Kim-1 ϩ/ϩ TECs readily bound apoptotic cells and formed phagocytic cups around them in contrast to Kim-1-deficient TECs (arrows, Fig. 8D) .
A major limitation of our data thus far was that we used apoptotic thymocytes to study efferocytosis, when in AKI the source of apoptotic cells would have been neighboring TECs subjected to lethal ischemia and/or reperfusion injury (15) . To formally test whether primary TECs can efficiently engulf apoptotic or necrotic TECs, we generated apoptotic or necrotic primary TECs from Kim-1 ϩ/ϩ mice and confirmed cell death using annexin V and PI staining (Fig. 8E ). We then fed equal numbers of apoptotic or necrotic TECs to live primary TECs isolated from either Kim-1 ϩ/ϩ or Kim-1 Ϫ/Ϫ mice, respectively. In keeping with our data thus far, we observed that TECs from Kim-1 ϩ/ϩ mice efficiently engulfed apoptotic TECs. Much to our surprise, we observed no significant phagocytosis of necrotic TECs by live TECs (Fig. 8F) . Moreover, TECs from Kim-1 Ϫ/Ϫ were unable to take up either apoptotic or necrotic cells.
Finally, to test whether G␣ 12 negatively regulates KIM-1dependent efferocytosis in primary TECs, we treated TECs isolated from Kim-1 ϩ/ϩ mice with G␣ 12 siRNA or control siRNA and compared their relative phagocytic efficiencies (104) . In keeping with what was observed in KIM-1-expressing HEK-293 cells, silencing G␣ 12 expression significantly increased efferocytosis by primary TECs (Fig. 8, G and H) .
DISCUSSION
KIM-1 is a phosphatidylserine receptor (29) that is specifically upregulated by TECs during ischemic or toxic AKI (42) (43) (44) , but the relevant intracellular signaling pathway(s) had not been appreciated until now. Here, we reveal for the first time that G␣ 12 negatively regulates KIM-1-dependent efferocytosis. Furthermore, we showed that G␣ 12 mediates this inhibition via downstream activation of RhoA. Given that KIM-1-mediated efferocytosis has been shown to protect against AKI (48, 110) and our data demonstrate that KIM-1 is indispensable for efferocytosis ( Fig. 8C ) by renal TECs, we conclude that G␣ 12 -RhoA signaling likely plays an important role in regulating efferocytosis by TECs during AKI.
Our findings here are supported by our previous work demonstrating that KIM-1, when upregulated following IRI, binds directly to G␣ 12 and inhibits its activation in TECs by blocking GTP loading onto it (48) . We also showed that Kim-1-deficient mice exhibit higher levels of active G␣ 12 (due to ROS) in the kidneys and worse kidney function following renal ischemic injury. Since ROS-mediated activation of G␣ 12 had been shown to activate downstream injury pathways (e.g., destabilizes tight junctions via Src kinase) downstream (113) , we deduced that KIM-1-mediated inhibition of G␣ 12 was at least partly important for renal protection from IRI.
Our findings here suggest that the ability of KIM-1 to suppress G␣ 12 activation is likely also crucial for TECs to carry out efferocytosis during AKI. This finding is particularly relevant because Yang et al. (110) recently showed that KIM-1-mediated efferocytosis by TECs reduced acute injury to the kidneys during IRI. Thus we propose that the upregulation of KIM-1 on TECs during AKI and subsequent inhibition of G␣ 12 protect from renal damage during renal IRI via at least two potential mechanisms. The first mechanism would be by blocking ROS-mediated activation of injury pathways via activated G␣ 12 that lead to worse tissue damage and impaired repair (109, 113) . The second mechanism would be by enhancing the phagocytic clearance of apoptotic cells by surviving TECs (32, 42) . It is likely that by inhibiting G␣ 12 in TECs KIM-1 would indirectly help limit inflammation and secondary tissue damage caused by spillage of intracellular contents from uncleared apoptotic cells undergoing secondary necrosis (24, 84, 96) . Interestingly, Kim-1-deficient mice (48) exhibited much more tissue damage and organ dysfunction from renal IRI compared with mice expressing a mutant form of Kim-1 (mucin domain deletion mutant) with an intact cytosolic domain (110) capable of interacting with endogenous G␣ 12 in TECs. Overall, we propose that KIM-1 (via its action on G␣ 12 ) profoundly influences TEC biology and thereby the renal response to AKI (7, 44) .
Actin cytoskeletal rearrangement is crucial for engulfment of apoptotic cells by phagocytes (10, 11) . Rac1 and RhoA belong to the RHO family of GTPases that regulate actin cytoskeletal reorganization (85) and have been implicated in efferocytosis (83) . The reciprocal role for Rac1 and RhoA in KIM-1-dependent phagocytosis by TECs proposed by our work is novel and is consistent with what has been reported by several others studying other phosphatidylserine receptors (27, 76, 100) . In these studies, the inhibitory effect of RhoA on apoptotic cell clearance was mediated by ROCK, as was the case in our experiments (100) . Activated RhoA increases the kinase activity of ROCK, which in turn phosphorylates myosin light chain and promotes contractility via actin stress fiber formation (87) . Therefore, one potential mechanism by which RhoA inhibited efferocytosis in our studies might be by increasing cell contractility via stress fiber formation (19, 83) . In contrast to RhoA, activated Rac1 is known to have an evolutionarily conserved and positive role in efferocytosis (38, 53, 75) . Rac1 is recruited to help form phagocytic cups composed of actin patches and generate membrane ruffles necessary to facilitate corpse engulfment (57, 75) . Rac1 is then downregulated when the phagocytic cup closes in conjunction with abrupt disruption of the actin patches. Our data are consistent with the requirement for Rac1 in efferocytosis. Whether one or more of the conserved phagocytic signaling pathways that regulate Rac1 activation in other phagocytes are involved downstream of KIM-1 in TECs remains to be tested (53, 99) . Moreover, the opposing roles of RhoA and Rac1 in KIM-1mediated efferocytosis might suggest a spatiotemporal pattern of activation that may be better visualized through use of TECs were cultured on glass coverslips and fed green-labeled AC for 3 h. Cells were fixed and surface stained for mouse Kim-1 using an anti-mouse Kim-1 antibody and Cy5-conjugated secondary antibody (ϫ600; bars ϭ 10 m). E: TECs isolated from wild-type C57BL/6 mice were left untreated (live), subjected to UV for 3 min, followed by incubation overnight (to stimulate apoptosis), or subjected to heat shock at 65°C for 15 min (to stimulate necrosis). The different type of cell death was confirmed using PI and annexin V staining followed by flow cytometry. Data represent 3 independent experiments. F: live, apoptotic, or necrotic cells labeled with pHrodo Red were fed to either Kim-1 ϩ/ϩ or Kim-1 Ϫ/Ϫ TECs, and the percentage of phagocytosis was measured using flow cytometry (n ϭ 3) **P Ͻ 0.005 by unpaired t-test. G: TECs isolated from wild-type C57BL/6 mice were transfected with 50 pmol of control siRNA or siRNA against mouse G␣12 for 24 h, and the level of G␣12, mouse Kim-1, and actin was determined by Western blotting. H: G␣12 siRNA-treated cells were subjected to phagocytosis assay, and the percentage of phagocytosis of pHrodo-labeled AC was measured by flow cytometry (n ϭ 4). *P Ͻ 0.5 by unpaired t-test.
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G␣12 INHIBITS KIM-1-MEDIATED EFFEROCYTOSIS biosensors (and fluorescence resonance energy transfer) that respond to RhoA and Rac1 activation. To our knowledge, this is the first report describing phagocytic signaling pathways that govern KIM-1-mediated engulfment of apoptotic cells despite the fact that members of the TIM family of phosphatidylserine receptors that include KIM-1 [also known at T-cell immunoglobulin and mucin domain protein-1 (TIM-1)], TIM-3, and TIM-4 have been the subject of much research (4, 5, 14, 29, 67, 112) . Studies on TIM-1 signaling thus far have focused primarily on its nonphagocytic functions, for instance, on costimulation of T cell responses (4, 7, 16, 61, 67) . Balasubramanian et al. (4) reported that TIM-1 mediates the degradation of NUR77, a nuclear receptor implicated in apoptosis and cell survival, but did not investigate efferocytic signaling in their studies. Additionally, Yang et al. (110) demonstrated that KIM-1 interacts with p85 in TECs and downmodulates NF-B signaling. TIM-3 is expressed by T cells and dendritic cells where it mediates phagocytosis of apoptotic cells, but very little is known regarding how it mediates phagocytic signaling (73, 77, 90) . Tim-4 on the other hand has been shown to not directly mediate phagocytic signaling (81) . Although various GTPases make up fundamental components of the phagocytic signaling machinery (39, 83) , to our knowledge our study is the first one to implicate G␣ 12 in efferocytosis. Given the various fundamental processes that G␣ 12 regulates, such as motility (52), modulation of cell-cell junctions (69) , cellular transformation (22) , and contractility (8, 33) , our study might suggest a relationship between these processes and efferocytosis in TECs, particularly during AKI. For example, pathological activation of G␣ 12 during IRI results in activation of injury pathways via destabilization tight junctions (89) through its interaction with zonula occludens-1 (ZO-1) and Src kinase (69, 70, 88) . The disruption of tight junctions has been shown to be a hallmark of epithelial cell damage in IRI and is believed to be a contributor to kidney dysfunction that often ensues (21, 71) . The relationship between tight junction assembly and disassembly during efferocytosis has not been studied to date.
All in all, deciphering KIM-1 signaling pathway(s) may be of clinical significance to those treating AKI. Our work presented here and previously suggests that targeting G␣ 12 might be a potential strategy to treat AKI by enhancing clearance of apoptotic cells and simultaneously inhibiting downstream injury pathways. Unfortunately, there is no specific G␣ 12 inhibitor available to currently test this in vivo. Nonetheless, our detailed work uncovering the importance of KIM-1 in TEC efferocytosis and how it is regulated offers important insights into TEC biology that might be relevant to AKI. 
